Toxicity assessment of silver nanoparticles against Escherichia coli strains isolated from horse dung
Source abstract
Abstract
On account of the spread of the phenomenon of microorganisms developing drug resistance, new and more effective methods for fighting pathogens are being sought. Therefore, silver nanoparticles (AgNPs) are increasingly used in various fields of industry and medicine due to their bactericidal properties. The aim of this work was to assess the toxicity of nanosilver prepared by chemical reduction process against Escherichia coli strains isolated from horse dung. AgNPs were prepared by chemical reduction involves the reduction of silver salt by a reducing agent in the presence of suitable stabiliser, which is necessary in protecting growth of AgNPs through aggregation. The environmental strains were isolated from horse dung, then identified and evaluated for their sensitivity to AgNPs using the disk diffusion method. Tested AgNPs suspensions exhibit strong antimicrobial activity. The minimum inhibitory concentration of bacterial isolates was found to be 15 μg/mL, AgNPs resistance level for each tested strain were significantly diversified.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticles: synthesis and applications · Healthcare and Environmental Waste Management · Pharmaceutical and Antibiotic Environmental Impacts
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Microbiology University of Agriculture in Cracow Mickiewicza Ave 24/28 30‐059 Cracow Poland
Institute of Inorganic Chemistry and Technology Cracow University of Technology Cracow 31155 Poland
References (59)
Show source-provided references
1. 10.1007/3-540-29838-X10.1007/3-540-29838-X ↗
2. Nanotechnology the present and the future
3. 10.1016/j.mseb.2007.06.01410.1016/j.mseb.2007.06.014 ↗
4. 10.32725/jab.2008.01510.32725/jab.2008.015 ↗
5. Kelsall R.W. · 2008
6. 10.1007/s00339‐008‐4807‐510.1007/s00339‐008‐4807‐5 ↗
7. 10.1007/s00449‐008‐0224‐610.1007/s00449‐008‐0224‐6 ↗
8. 10.1049/mnl.2011.015210.1049/mnl.2011.0152 ↗
9. 10.1016/j.saa.2004.09.01410.1016/j.saa.2004.09.014 ↗
10. 10.1088/0957‐4484/18/14/14560110.1088/0957‐4484/18/14/145601 ↗
11. 10.1016/j.nano.2012.02.00710.1016/j.nano.2012.02.007 ↗
12. Metal nanoparticles preparation under microwave irradiation using selected reductive‐stabilizing substances
13. 10.1016/S1003‐6326(13)62625‐410.1016/S1003‐6326(13)62625‐4 ↗
14. MalinaD.SobczakA.WzorekZ.: ‘The chemical methods of silver nanoparticles synthesis’.14th Conf. on Environment and Mineral Processing Part I Ostrava 3–5 June2010 pp.157–162 ISBN: 978‐80‐248‐2208‐3
15. 10.1016/j.colsurfb.2013.01.00310.1016/j.colsurfb.2013.01.003 ↗
16. 10.2174/157341371166615012622595110.2174/1573413711666150126225951 ↗
17. 10.1016/S0079‐6468(08)70024‐910.1016/S0079‐6468(08)70024‐9 ↗
18. 10.1016/j.electacta.2005.04.07110.1016/j.electacta.2005.04.071 ↗
19. 10.1021/pr050407910.1021/pr0504079 ↗
20. 10.1021/es801785m10.1021/es801785m ↗
21. 10.1021/es101072s10.1021/es101072s ↗
22. Positive and negative aspects of silver nanoparticles usage
23. 10.1128/AEM.02218‐0610.1128/AEM.02218‐06 ↗
24. Polish Equestrian Federationhttp://www.pzj.pl/
25. 10.1002/978047075228910.1002/9780470752289 ↗
26. Silver nanoparticles synthesis with different concentrations of polyvinylpyrrolidone
27. Synthesis and physicochemical characteristics of the silver nanoparticles and evaluation of their toxicity to fungi of the species Fusarium culmorum isolated from winter wheat
28. 10.1016/j.colsurfb.2015.06.05610.1016/j.colsurfb.2015.06.056 ↗
29. 10.1021/pr100047q10.1021/pr100047q ↗
30. 10.2217/fmb.10.12710.2217/fmb.10.127 ↗
31. 10.1111/j.1574‐6976.2011.00298.x10.1111/j.1574‐6976.2011.00298.x ↗
32. Application of MALDI‐TOF MS for identification of clinical isolates of bacteria from humans and animals10.5604/01.3001.0004.1302 ↗
33. 10.1016/j.nano.2007.02.00110.1016/j.nano.2007.02.001 ↗
34. 10.1016/j.jcis.2014.11.07410.1016/j.jcis.2014.11.074 ↗
35. European Committee on Antimicrobial Susceptibility Testing: ‘Clinical breakpoints – bacteria (v. 6.0)’.2016 http://ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public_consultation_clinical_microbiology_infection_article.aspx
36. 10.1016/S0140‐6736(75)91138‐110.1016/S0140‐6736(75)91138‐1 ↗
37. 10.1128/CMR.12.1.14710.1128/CMR.12.1.147 ↗
38. 10.1016/S0168‐6445(03)00047‐010.1016/S0168‐6445(03)00047‐0 ↗
39. 10.1016/j.jhin.2004.11.01410.1016/j.jhin.2004.11.014 ↗
40. 10.1111/j.1742‐481X.2008.00563.x10.1111/j.1742‐481X.2008.00563.x ↗
41. 10.1007/s40097‐014‐0082‐510.1007/s40097‐014‐0082‐5 ↗
42. Schmitz F.J. · 2004
43. 10.1128/jb.179.19.6127‐6132.199710.1128/jb.179.19.6127‐6132.1997 ↗
44. 10.1038/296642a010.1038/296642a0 ↗
45. 10.1007/BF0020519410.1007/BF00205194 ↗
46. 10.1007/BF0027629910.1007/BF00276299 ↗
47. 10.1016/0147‐619X(92)90008‐X10.1016/0147‐619X(92)90008‐X ↗
48. 10.1128/JB.185.13.3804‐3812.200310.1128/JB.185.13.3804‐3812.2003 ↗
49. 10.1007/s10295‐006‐0139‐710.1007/s10295‐006‐0139‐7 ↗
50. 10.1002/jps.2400110.1002/jps.24001 ↗
51. 10.1021/nn900277t10.1021/nn900277t ↗
52. 10.1088/0957‐4484/16/10/05910.1088/0957‐4484/16/10/059 ↗
53. 10.1007/s10856‐011‐4360‐110.1007/s10856‐011‐4360‐1 ↗
54. 10.1186/1477‐3155‐10‐110.1186/1477‐3155‐10‐1 ↗
55. Biogenic synthesis of nanosilver and its antibacterial effect against resistant gram negative pathogens
56. Synthesis, characterization, and evaluation of antibacterial effect of Ag nanoparticles against Escherichia coli O157:H7 and methicillin‐resistant Staphylococcus aureus (MRSA)
57. A study on the minimum inhibitory concentration and minimum bactericidal concentration of nano colloidal silver on food‐borne pathogens
58. 10.5812/jjm.872010.5812/jjm.8720 ↗
59. 10.1007/s13204‐014‐0381‐710.1007/s13204‐014‐0381‐7 ↗